Clinical Trial

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Study acronym: MAESTRA 1
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will evaluate the safety and efficacy of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer (PROC) With Cyclin E1 Overexpression.
Protocol Amendment History 2 changes
notable Trial sites reduced: 79 -> 74 locations 2026-07-21
notable Trial sites reduced: 82 -> 79 locations 2026-05-27
Trial Details
NCT Number NCT07023627
Lead Sponsor Incyte Corporation
Collaborators: ENGOT Foundation, GOG Foundation
Conditions Ovarian Cancer
Enrollment 160 participants
Start Date 2025-11-12
Primary Completion 2027-04-27 (estimated)
Study Completion 2027-10-24 (estimated)
Updated on ClinicalTrials.gov 2026-08-06